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tissue damage causes release of systemic inﬂammatory mediators that promote endothelial leak, extravascular
ﬂuid shifts, and cardiovascular derangement. This phase is characterized by relative intra-vascular hypovolaemia
and poor peripheral perfusion. Large volume intravenous ﬂuid resuscitation is generally required. The patients'
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namic perturbation. At all times, drug distribution, metabolism, and elimination are grossly distorted. For hydro-
philic agents, changes in volume of distribution and clearance are marked, resulting in potentially sub-optimal
drug exposure. In the case of antibiotics, thismay then promote treatment failure, or the development of bacterial
drug resistance. As such, empirical dose selection and pharmaceutical developmentmust consider these features,
with the application of strategies that attempt to counter the unique pharmacokinetic changes encountered in
this setting.icine, Facult
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Burn injury represents a unique form ofmajor trauma, characterized
by severe skin and soft tissue damage, most frequently due to the appli-
cation of heat energy. Separate categories include scalds, contact burns,
ﬁre, chemical, electrical, and radiation exposure. Liquids, steam or
grease can cause scalds, while ﬁre burns are often divided into ﬂash
and ﬂame injuries [1]. Chemical, electrical, and radiation burns can re-
sult in deep tissue injury, with unique decontamination, safety, and
therapeutic considerations. Depending on the depth and extent of the
burn, profound systemic inﬂammatory changes can result in signiﬁcant
organ dysfunction, distant to the site of injury [2]. Major burn injury can
have devastating effects on individuals and their families, not just in
terms of crude mortality, but also long-term functional disability and
psychosocial morbidity.
Prolonged hospitalization and intensive care unit (ICU) admission
are frequently required in these scenarios, particularlywhere the extent
of burns is signiﬁcant (N20–30% total body surface area) or where there
has been airway involvement [3]. Large volume intravenous (IV) ﬂuid
resuscitation, hemodynamic instability, respiratory support, repeated
surgical intervention, end-organ dysfunction, metabolic derangement,
and nutritional deﬁciency typically characterize the patients' course
[4]. In addition to local wound management, numerous parenteral and
enteral pharmacological therapies are provided. These routinely include
sedatives, analgesics, anxiolytics, venous thromboembolism and gastric
ulcer prophylaxis, aperients, multivitamins, trace elements, and antibi-
otics. Each has unique pharmacokinetic (PK) and pharmacodynamic
(PD) characteristics, which are variably inﬂuenced by the signiﬁcant
pathophysiological changes encountered with major burn injury [5].
Antibiotic therapy is especially suited to a discussion of these consid-
erations, as these agents do not have an easily measurable ‘end of
needle’ pharmacological effect. In this fashion, the clinician is not
immediately aware as to the adequacy of treatment, as is the case
with other therapies, such as the relief of pain and discomfort with an-
algesics. In addition, adequate antibiotic therapy in the setting of severe
infection has been repeatedly associated with improved patient out-
comes [6–8], is now regarded as a quality of care indicator [9], and
may signiﬁcantly impact the development of future antimicrobial resis-
tance [10]. However, confounding accurate dosing is themarked chang-
es in PK encountered in this setting [11,12], such that prescriptions
based on those used in an ambulatory setting, are likely to be grossly
ﬂawed.
This review articlewill highlight these issues by exploring the effects
of major burn injury on antibiotic PK/PD, as a template for considering
the use of any pharmacological therapy in this setting. Importantly,
the diagnosis of infection itself is particularly challenging in this setting,
as the profound systemic inﬂammatory response encountered in major
burns results in clinical features often indistinguishable from that of
sepsis. Clinicians therefore ﬁnd it difﬁcult to conﬁdently diagnose infec-
tion in burns patients, although approaches to this clinical dilemmawill
not be reviewed in this paper.2. Major burn injury
2.1. Epidemiology
Globally, an estimated 265,000 deaths occur every year due tomajor
burns [13]. Importantly, incidence, severity, and outcomes demonstrate
substantial geographic variability, with 90% of burns occurring in low to
middle income countries [14]. In the European Union, the reported an-
nual incidence of severe burns is between 0.2 and 2.9 per 10,000inhabitants [15]. Approximately 60% were male, and mortality ranged
from 1.4 to 18%. Flame injuries and scalds are the most common causes
of burnsworldwide [16,17], with themost vulnerable groups being chil-
dren less than four years of age [18], women [19], and older adults (over
the age of 60 years) [20]. In Australia and New Zealand, themedian hos-
pital length of stay following admission to a burns unit (between 2010
and 2014) was 5.6 days; 14.5% required ICU admission, and overall in-
hospital mortality was 1.5% [3]. Importantly, key indicators of likely
mortality are the extent of injury – e.g. total body surface area (TBSA)
involved, the presence of an inhalational injury, and older age [21–23].
2.2. Pathophysiological changes
Major burn injury is deﬁned as a surface area involvingN20–30%
TBSA, and classically is characterized by a bi-phasic systemic response.
During the ﬁrst 48 h, the severity and extent of local tissue injury results
in inﬂammatory mediators being released into the systemic circulation.
These induce speciﬁc haemodynamic alternations, including increased
capillary permeability [24], peripheral and splanchnic vasoconstriction
[25], and myocardial depression [26]. Large volumes of protein rich
ﬂuid is lost into the interstitial space[27,28], resulting in relative intra-
vascular hypovolaemia, systemic hypotension and organ hypoperfu-
sion. Modern burns resuscitation protocols therefore call for the
delivery of large quantities of IV ﬂuid, in order to restore circulating
plasma volume, and ideally prevent further organ dysfunction [29].
The Parkland formula (based on the percentage TBSA burnt) [30], is
commonly used to determine the estimated ﬂuid deﬁcit, although pa-
tients will often receive variable volumes of ﬂuid, leading to over or
under-resuscitation [31,32].
Other organ support modalities are often instituted during this peri-
od, including endotracheal intubation and mechanical ventilation, cen-
tral venous access and vasopressor infusion, and renal replacement
therapy [32]. Respiratory failure is often multifactorial, and may result
from primary injury to the lungs and airways from direct thermal inha-
lation, or may be a secondary phenomenon due towidespread systemic
inﬂammation [33]. Acute kidney injury (AKI) can occur in up to 25–30%
of cases [34], withmortality increasingwith worsening severity [35,36].
Initial surgical debridement (typically requiring signiﬁcant blood prod-
uct administration and complicated by coagulopathy) is often per-
formed at this time.
The second phase of major burns injury is characterized by a hyper-
metabolic state, in part mediated by elevated concentrations of endog-
enous catecholamines, and oxidative stress [37]. Supraphysiologic
thermogenesis, cardiac work, and resting energy expenditure are all
hallmarks of this state [38]. Cardiac output and major organ blood
ﬂoware typically increased, systemic vascular resistance is low. Acceler-
ated catabolism and reduced constitutive protein synthesis results in a
negative nitrogen balance [39], necessitating strict attention to protein
and energy delivery. Frequent surgical intervention is required, to
ensure adequate debridement, change dressings, or complete skin
grafting.
2.3. Antibiotic therapy in burns injury
Almost all major burns patients will manifest signs of profound sys-
temic inﬂammation and/or organ dysfunction. Tachypnoea, tachycar-
dia, fever, and plasma leukocytosis, are almost universally present in
the critically ill [40]. Cardiovascular, respiratory, renal, and haematolog-
ical dysfunction are common, such that distinguishing new onset organ
impairment is challenging. Clinically diagnosing sepsis (host mediated
organ dysfunction secondary to infection) is therefore difﬁcult [41],
Fig. 1.Graphical illustration of the impact of major burns injury on the pharmacokinetics of hydrophilic antibiotics. * Δ depends on the sieving coefﬁcient and saturation coefﬁcient of the
antibiotic (both depending on level of protein binding), mode of renal replacement therapy (either pre- or postdilution and either ﬁltration or dialysis), the dose of renal replacement
therapy and the actual dose delivered (taking into account interruptions, clotting of the ﬁlter, etc.). Vd – volume of distribution.
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patients are highly susceptible to nosocomial infection, due to loss of
skin integrity, the requirement for long periods of invasive organ sup-
port, and a degree of functional immunosuppression [42]. In this fash-
ion, although there is no role for prophylactic systemic antibiotic
therapy inmajor burn injury [43],most patientswill require a treatment
course at some point during their in-hospital stay [44,45].
The choice of antibiotic agent should be guided by microbiological
data [46], both local antibiogram and patient surveillance data, where
available. Fungal colonization and infection often complicate large
burns, and therefore adequate anti-fungal therapymust also be consid-
ered [47–49]. Importantly, multidrug resistant pathogens are an in-
creasing problem in this setting [50], such that pharmacotherapy with
less familiar agents, with signiﬁcant potential side effects, are being in-
creasingly employed [51]. Due to the profound physiological changes
associated with major burns, the PK of these agents are signiﬁcantly
distorted [52], such that the application of‘standard’ doses are likely to
result in sub-optimal concentrations (either sub- or supra-therapeutic),
and clinical failure or drug toxicity.Fig. 1 graphically illustrates this
paradigm.
3. PK/PD alterations in major burns – as exempliﬁed by antibiotics
3.1. Basic antibiotic PK/PD
While an in depth review of antibiotic PK/PD is beyond the scope of
this paper, a basic pharmacological framework is required to appreciate
the impact ofmajor burns on drughandling and efﬁcacy. PK refers to the
change in drug concentration (ideally at the effect site) over time, and is
a reﬂection of the processes involved in absorption, distribution,metab-
olism, and excretion. For antibiotics, speciﬁc physicochemical proper-
ties (e.g. molecular weight, and lipid solubility), degree of protein
binding, and the elimination pathways involved, are crucial in deter-
miningdrug handling. PD involvesmeasuring drug effect, typically illus-
trated by a concentration-effect relationship. In the case of antibiotics,
this describes the ability to kill or inhibit the growth of a bacterial path-
ogen. Inherent susceptibility to any speciﬁc agent is quantiﬁed by the
minimum inhibitory concentration (MIC), measured in vitro. PK/PD in-
tegrates all this information, and describes the optimal drug exposurerequired formaximal bacterial killing [53]. According to the PK/PD char-
acteristic, antibiotics can exert concentration-dependent, time-depen-
dent, and concentration/time-dependent killing.
Aminoglycosides (gentamicin, tobramycin, amikacin) represent the
most extensively studied concentration-dependent group [54], where-
by drug exposures deﬁned by a maximum plasma concentration to
MIC ratio (Cmax:MIC) of at least 10, have been associated with greater
efﬁcacy [55,56]. Beta-lactams (penicillins, cephalosporins, carbapen-
ems) are the most frequently prescribed time-dependent agents [57,
58], with animal studies suggesting that the time above MIC (fTNMIC) –
e.g. that fraction of the dosing intervalwhere unbound (free) concentra-
tions remain above the MIC, is a keymetric of drug exposure. Targets of
at least 40–70% of the dosing interval are required to ensure adequate
bacterial killing [59]. Indeed, a large multicenter pharmacokinetic
point-prevalence study of critically ill patients receiving beta-lactams,
demonstrated a three-fold greater risk of inferior treatment outcomes
in those where 50% fTNMIC was not achieved [6]. Moreover, additional
(albeit limited) data suggests that even higher drug exposures (4–5
× MIC for 90–100% of the dosing interval) may be required to ensure
clinical success in some clinical scenarios [60,61].
Antibiotics displaying both time- and concentration-dependent
characteristics include the glycopeptides [62] (vancomycin,
teicoplanin), and ﬂuoroquinolones [63] (ciproﬂoxacin, moxiﬂoxacin,
levoﬂoxacin). In this case, achieving adequate area under the plasma
concentration time curve to MIC ratios (AUC0–24/MIC) is considered
critical for efﬁcacy. Speciﬁcally, values of at least 400 have been
shown to improve outcomes in vancomycin treated methicillin-resis-
tant Staphylococcus aureus (MRSA) lower respiratory tract infection
[64]. Similarly, AUC0–24/MIC ratios N125 for gram-negative [63], and
N30 for gram-positive infections [65], are reported necessary for suc-
cessful ciproﬂoxacin therapy. Importantly, ratios b100 may promote
the emergence of bacterial resistance [66,67].
Although currently there are no large-scale clinical trial data quantify-
ing the clinical effect of achieving antibiotic PK/PD targets, they do repre-
sent logical end-points for pharmacologically robust empirical dosing. For
the clinician, the challenge exists in translating these largely animal in
vivo data into clinical practice, in addition to tailoring therapy to major
burns victims. Moreover, in a relatively unique fashion sub-optimal anti-
biotic exposure can not only lead to treatment failure, but can also have
Fig. 2.Concentration-time curves illustrating thepharmacokinetics/pharmacodynamics of
antimicrobial agents according to pathophysiological changes that might occur following
severe burn injury[148].Cmax, antibiotic peak concentration; AUC, area under the
concentration-time curve; Cmin, antibiotic trough concentration. *In case of increased Vd,
the T N MIC can be increased following the ﬁrst dose. At steady-state concentrations
however, the T NMIC is prolonged because of increased half-life.
After J. Roberts et al. [148].
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the development of bacterial resistance and therapeutic redundancy.
3.2. Absorption
As the vast majority are administered intravenously, altered absorp-
tion via the gastrointestinal (GI) tract or subcutaneous tissues, has little
bearing on antibiotic PK inmajor burn injury patients. However,multiple
othermedications used in burnmanagement are routinely administered
via non-intravenous routes, such as beta-blockers and gastric ulcer pro-
phylaxis (GI tract), venous thromboembolism prophylaxis (subcutane-
ous), and nicotine replacement therapy (transdermal). During theimmediate phase post-burn injury, peripheral and splanchnic vasocon-
striction [25] is likely to signiﬁcantly impair drug absorption via these
routes, while conversely, during the hypermetabolic phase, perfusion
and therefore absorption is plausibly increased. Indeed, local trauma
and inﬂammation at the site of burn wounds may have variable effects
on drug absorption, depending on underlying tissue viability. The use
of vasopressor therapy will also inﬂuence this signiﬁcantly. Moreover,
separate to changes in perfusion, GI dysfunction is a common complica-
tion post-major burns [68], whichwill considerably impact the PK of any
enterally administered drug.
3.3. Volume of distribution (Vd)
Key intrinsic properties that determine drug distribution include;
molecular weight, degree of ionization, lipid solubility and protein
binding. More lipophilic agents, such as the ﬂuoroquinolones, have a
larger Vd, and greater tissue distribution. In contrast, hydrophilic mole-
cules (such as the aminoglycosides and beta-lactams) are principally
restricted to the extracellular space, resulting in a relatively small
(~0.2 L/kg) Vd[69]. However, in major burns injury this can be signiﬁ-
cantly increased, principally as a result of the widespread capillary
leak, interstitial oedema formation, and aggressive large volume IV
ﬂuid resuscitation. Not unexpectedly, highly variable and unpredictable
drug concentrations have been noted in this setting [70]. Fig. 2a illus-
trates the alterations in PK/PD in case of increased Vd.
Jeon and colleagues recently conﬁrmed these assertions in their pop-
ulation PK analysis of piperacillin in ﬁfty burn patients. Piperacillin Vd
was estimated at 41.4 L at baseline, increasing to 56.2 L in those that
were considered septic [71]. This represents a 4–5 fold increase in com-
parison to healthy volunteers [72], and a 1.5–2 fold increase compared
with septic critically ill patients [73]. Similar changes in Vd have also
been reported with other beta-lactams, such as meropenem [74],
imipenem [75], and ceftazidime [76]. Of note, previous work exploring
the subcutaneous distribution of cefalotin in major burns has demon-
strated equivalent tissue exposures in both burn and non-burn sites
[77], albeit this is likely to be inﬂuenced signiﬁcantly by burn depth
and tissue viability.
For concentration dependent antibiotics a larger Vd also represents a
critical change in PK, as lower plasma concentrations are likely, if stan-
dard doses are employed. Indeed, data from nine burns patients has
demonstrated a signiﬁcant increase in daptomycin Vd, associated with
a 44% reduction in Cmax[78]. Similar ﬁndings have also been noted
with amikacin, where higher daily doses were recommended [79].
3.4. Protein binding
The unbound (free) fraction of a drug (fu)mediates its pharmacolog-
ical effects and any potential toxicity, in addition to being available for
elimination [11]. This reinforces the greater utility in measuring free
(as opposed to total) drug concentrations [80]. Albumin is the predom-
inant circulating plasma protein, and binds acidic antibiotics, such as
ceftriaxone [81], ﬂucloxacillin [82], teicoplanin [83], daptomycin [78],
and ertapenem [84]. Of note, hypoabluminaemia (plasma albumin
concentration b 25 g/L) is generally a common ﬁnding in the critically
ill [85], as albumin concentrations fall as part of the acute phase reac-
tion. With major burns injury, hypoalbuminaemia is even more pro-
nounced [86]. This is principally related to the loss of protein-rich ﬂuid
via the burnwound, a decrease in constitutive hepatic protein synthesis,
and an increase in catabolism. For highly bound drugs (N90%), this will
signiﬁcantly distort the PK proﬁle, due to an increase in fu. In contrast,
alpha-1 acid glycoprotein synthesis increases post-burn injury, leading
to a decrease in fu for basic drugs which bind this carrier [87] (e.g.
rifampicin).
Importantly, for those agents that principally distribute into the ex-
tracellular space, a greater fu is associatedwith a larger Vd[88]. Similarly,
for drugs that are renally cleared, a higher fu also results in more rapid
69A.A. Udy et al. / Advanced Drug Delivery Reviews 123 (2018) 65–74elimination from the systemic circulation [78,81–84,89]. In such a sce-
nario, the combination of a larger Vd, with more rapid clearance (CL),
will predispose to sub-optimal concentrations for signiﬁcant periods,
particularly toward the end of the dosing interval [90].
3.5. Clearance (CL)
The principal mechanisms for drug elimination in major burns in-
volves either renal clearance (CLR), through a combination of glomeru-
lar ﬁltration and/or renal tubular excretion, or non-renal clearance
(CLNR). CLNR pathways include hepatic metabolism and/or biliary excre-
tion, non-enzymemediated degradation, and direct loss of substrate via
ongoing wound exudate. Renal function following major burn injury is
highly variable, and is best considered by examining the spectrum of
kidney function encountered, namely; augmented renal clearance
(ARC) and AKI requiring institution of renal replacement therapy.
Fig. 2b and c illustrate the alterations in PK/PD in case of augmented
renal clearance and impaired renal function, respectively.
3.5.1. Acute kidney injury requiring continuous renal replacement therapy
AKI can frequently complicate the course of many major burn pa-
tients [34]. Notwithstanding any kidney injury incurred during the ini-
tial phase (secondary to a reduction intravascular volume, cardiac
output, and major organ blood ﬂow), the utilization of nephrotoxic
medications, radio-contrastmedia, and the subsequent nosocomial sep-
sis, can all contribute to a deterioration in renal function. As the kidney
progressively fails, worsening azotaemia (typically identiﬁed by rising
plasma creatinine concentrations), acid-base alterations, electrolyte ab-
normalities and ﬂuid overload are all potential complications. As such,
the Vd of hydrophilic antibiotics can increase [91–93]. However, as the
majority of these agents are cleared via the kidneys, the major PK con-
sequence is a reduction in CLR. As such, clinicians often reduce dosing
[69], in order to avoid drug accumulation and potential toxicity.
In the case of concentration-dependent agents (e.g. aminoglyco-
sides), this is best achieved by extending the dosing interval, as com-
pared to time-dependent antibiotics (beta-lactams), where the
amount administered can be reduced, while maintaining a similar dos-
ing frequency. Importantly, CLNR can be substantially altered in these
circumstances (see below) [94], and in combination with an increase
in Vd, may not necessarily mandate any immediate dose reduction
[95,96]. In this case, early aggressive antibiotic therapy is typically war-
ranted with major burn injury, such that non-AKI dosing should be
employed initially (typically for the ﬁrst 24–48 h of treatment), regard-
less of renal function [97]. If using aminoglycosides and vancomycin,
therapeutic drug monitoring (TDM) is particularly useful in guiding
ongoing therapy [98], and may also be used to infer some information
about the likely dosing requirements for other renally cleared drugs.
TDM for other antimicrobials is being increasingly reported to show
that it can increase the achievement of PK/PD targets [99]. Indeed
TDM should be used where available for this reason, although clinical
outcome data further supporting its role in burns patients is limited.
Signiﬁcantly confounding this situation, is the application of extracor-
poreal support modalities, such as continuous renal replacement therapy
(CRRT), intermittent haemodialysis (IHD), and slow low efﬁciency dialy-
sis (SLED). Factors such as molecular weight, protein binding, mode of
renal replacement therapy (dialysis versus ﬁltration), ﬁlter porosity,
blood ﬂow rate, and total efﬂuent rate, will all inﬂuence PK [100]. Clinical
factors, including timing of CRRT, ﬁlter lifespan, and residual native renal
function [101], will also impact drug exposure. Dosing decisions are
therefore largely empirical, and based on data extracted from non-burn
populations. Intra- and inter-patient variability is likely to be signiﬁcant,
potentially resulting in sub-therapeutic concentrations. Recent data
from Jamal and colleagues exploring the impact of CRRTprescription, sug-
gests that total efﬂuent ﬂow rate is an important predictor of extracorpo-
real beta-lactam clearance [102].3.5.2. Augmented renal clearance (ARC)
ARC corresponds to the elevated renal elimination of circulating sol-
ute (such aswaste products and drugs) [103], and is a phenomenon that
has been repeatedly observed in burns victims [104,105]. As such, this
cohort represents a major at-risk group. The biological mechanisms
are thought to principally involve greater renal blood ﬂow, and as a con-
sequence, increased glomerular ﬁltration (GFR) [106]. This is largely
driven by the underlying hyperdynamic circulatory state [107,108], a
reﬂection of ongoing systemic catabolism and inﬂammation. The infu-
sion of large volumes of IV ﬂuid and/or the application vasoactive med-
ications, may further enhance renal solute excretion [109]. Moreover,
the recruitment of ‘renal reserve’, whereby GFR increases in response
to protein loading, may also be implicated [110].
ARC will signiﬁcantly impact the PK of any agent that is primarily
renally cleared, such as hydrophilic antibiotics (glycopeptides, amino-
glycosides, and beta-lactams) and low-molecular weight heparins
[111]. In such cases, more rapid renal elimination pre-disposes to sub-
optimal drug concentrations [79], treatment failure [6], and drug resis-
tance [112], particularly for time-dependent agents [113,114]. Unfortu-
nately, facilities to evaluate drug clearance in daily practice are generally
lacking. Where TDM is available, repeat plasma concentrations can be
used to guide subsequent dosing [70], although in most circumstances
this is not possible. Moreover, routinely available biochemical markers
of renal function are not necessarily helpful, as they are typically report-
ed within the ‘normal’ reference range [115]. As such, identifying ARC
represents a signiﬁcant challenge in this context [104].
Numerous mathematical estimates of GFR have been developed for
clinical use. These include the Cockcroft-Gault formula [116], modiﬁca-
tion of diet in renal disease (MDRD) equation [117], and more recently
the chronic kidney disease epidemiology (CKD-EPI) eGFR [118]. Each
typically utilizes the plasma creatinine concentration, and a variety of
demographic and/or anthropometric parameters, such as age, gender,
height andweight. Albeit thesemeasures have greater utility than static
plasma biomarker concentrations, their application in major burns pa-
tients is inherently ﬂawed [104,119]. This speciﬁcally relates to the der-
ivation of these estimates, which primarily involve large cohorts of
ambulatory non-critically ill patients. As such, they fail to account for
the unique characteristics encountered in the burns population, and
cannot be relied upon to accurately identify ARC [120].
In this fashion, a timed urinary creatinine clearance (CLCR) has been
employed as a more dynamic measure of GFR in critical illness [115].
Importantly, this approach suffers from all of the limitations associated
with an endogenous ﬁltration marker, in that creatinine production is
unlikely to be at steady-state, and is intimately linked with baseline
muscle mass [121]. Similarly, creatinine is also excreted in the proximal
tubule, such that ameasured CLCRwill over estimate true GFR in the set-
ting of renal impairment [122]. Despite these caveats, CLCR has been
closely correlated with the renal clearance of exogenous ﬁltration
markers [106], and remains a widely available, minimally invasive,
cost-efﬁcient method for assessing renal function. Eight-hour collec-
tions appear to provide the best balance between feasibility and accura-
cy [123]. Moreover, CLCR measures ≥130 mL/min/1.73 m2 have been
linked with sub-therapeutic beta-lactam [113], and glycopeptide con-
centrations [124], and in this manner, serves as a useful threshold
above which alternative dosing strategies can be considered.
3.5.3. Non-renal clearance
Non-renal pathways for drug clearance include hepatic metabolism,
biliary excretion, non-enzymatic breakdown, and elimination via tissue
exudate and/or drain ﬂuid. In major burn injury, all of these mechanisms
may increase during the hypermetabolic phase, and have a signiﬁcant
effect on PK [106], although speciﬁc data for most drugs are lacking. Pre-
vious work investigating ethanol clearance post-major burn elegantly il-
lustrates this potential effect, with elimination rates being double that of
healthy individuals [125]. Notwithstanding this, emerging literature
stresses the importance of the hepatic response to thermal burn injury
Table 1
Proposed dosing of antibiotics in burn injury patients.
After [147].
Antibiotic agent Empirical dosage PK/PD target In case of moderate-severe renal
impairment (without renal replacement
therapy)
Amikacin Loading dose 30 mg/kg
Maintenance dose based on TDM, usually once daily
Cmax/MIC ≥8–10, AUC/MIC N70,
Cmin b2 mg/L
Maintain high doses if possible; prolong
dosing interval (36- to 48-h intervals are
acceptable)
Gentamicin Loading dose 7–10 mg/kg
Maintenance dose based on TDM, usually once daily
Cmax/MIC ≥10, AUC/MIC N70,
Cmin b0.5 mg/L
Maintain high doses if possible; prolong
dosing interval (36- to 48-h intervals are
acceptable)
Meropenem 1 g at 0, 4 and 8 h, thereafter 1 g every 8 h
Consider prolonged infusion (1 g infused over 3 h)
fT NMIC 40%; fT NMIC 100% if
immunocompromised
In case of intermittent dosing, dose can
be reduced or dosing interval prolonged.
Piperacillin/tazobactam 4/0.5 g at 0, 3 and 6 h, thereafter 4/0.5 g every 6 h
Consider continuous infusion
fT NMIC 50% (piperacillin); fT NMIC 100% if
immunocompromised
In case of intermittent dosing, dose can
be reduced or dosing interval prolonged.
Ciproﬂoxacin 400 mg/8 h or 600 mg every 12 h AUC/MIC ≥125, Cmax/MIC ≥8 Maintain high dose if possible while
prolonging dosing interval
Vancomycin Loading dose 30 mg/kg, thereafter 1 g every 8 h, 1.5 g
every 12 h or continuous infusion 30–40 mg/kg/day
Cmin 15–20 mg/L or steady state concentration
20–25 mg/L, AUC/MIC N400
Reduce total daily dose
Colistin Loading dose 9 million international units (IU)
colistimethate sodium (CMS), thereafter 9 million
IU/day divided in 2–3 doses
Steady state concentration ≥ 2 mg/L, fAUC/MIC
N25–35
Reduce dose or prolong dosing interval
Tigecycline Loading dose 100 mg, thereafter 50 mg every 12 h or a
200 mg loading dose followed by 100 mg every 12 h
Varying AUC/MIC targets for different pathologies
(e.g. pneumonia, intra-abdominal infection, soft
tissue infections)
No adaptations required
Linezolid 600 mg every 12 h AUC/MIC ≥85, T NMIC 85% Cmin N6 mg/L In case of severe renal impairment: 600
mg once daily
TDM, therapeutic drug monitoring; Cmax, antibiotic peak concentration; Cmin, antibiotic trough concentration; AUC, area under the concentration-time curve; MIC, minimal inhibitory
concentration; fT NMIC, time period in which the antibiotic concentration is higher than the MIC (expressed as % of the dosing interval).
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dysfunction is a common ﬁnding, with persistent and advanced hepatic
impairment being associated with greater mortality [127]. In such cir-
cumstances, the PK of agents that are extensively metabolised by the
liver may be deranged.
Importantly, withmajor burns, loss of skin integrity andwidespread
capillary leak can potentially result in large quantities of hydrophilic
drugs being lost in burn wound exudate [128–131]. Similarly, Adnan
and colleagues have previously demonstrated that relatively large
quantities of beta-lactams can be lost via high volume indwelling
drain tubes [132]. Given the ongoing inﬂammatory process that charac-
terizes major burn injury, such losses should be considered in empirical
dose selection, particularly with a difﬁcult to treat organism.4. Alternative dosing strategies
Given the substantial variation in PK encountered inmajor burn vic-
tims, alternative dosing strategies are required. With the Vd being sig-
niﬁcantly increased (particularly for hydrophilic agents), an adequate
loading dose is necessary [11]. In the case of antibiotics, this is essential,
in order to rapidly achieve therapeutic concentrations, which in turn
promotes fast, efﬁcient bacterial killing. For concentration dependent
agents, this is even more crucial, as adequate Cmax:MIC ratios are re-
quired [133]. Suitablyweight adjusted doses, which attempt to incorpo-
rate expansion of the extracellular space (e.g. ~30mg/kg adjusted body
weight amikacin or equivalent), aremandatory [79], while in the setting
of ARC, more frequent dosing (e.g. 12–18-hourly) may also be consid-
ered. Recommendations concerning adequate loading doses have also
been published for glycopeptides [134–136], beta-lactams [71,74], dap-
tomycin [78], and tigecycline [137], and reinforce the importance of this
strategy when initiating therapy.
Maintaining sufﬁcient drug concentrations (above theMIC of the like-
ly pathogen) over the entire duration of the dosing interval represents a
biologically attractive approachwhen employing time-dependent antibi-
otics [57]. Intermittent dosing results in a substantial decline in drug con-
centrations post bolus administration, both as a consequence of drug
distribution and clearance. In many cases, particularly in reference to
the trough plasma concentration, this is intimately linked withCLR[138].As such, in cases of ARC (which is highly prevalent following
major burns), more frequent dosing should be employed.Similarly,
continuous or extended infusions can be used, which offer a distinct PK
advantage [139,140], albeit adequate loading doses are still mandatory.
Whether this translates into improved clinical outcomes (greater clinical
cure or a reduction in the development of resistance), is uncertain, as
prior studies with beta-lactams [141–143] and glycopeptides [144,145]
have generated conﬂicting results. Importantly, in the case of ARC, a
higher daily dose is also likely to be required.
The marked PK derangement observed in major burns makes accu-
rate dosing problematic. Adequate weight based loading doses, more
frequent administration, or the use of continuous infusions represent
empirical strategies that may increase the probability of achieving ade-
quate drug concentrations. However, the lack of immediate clinical
feedback makes subsequent dose adjustment challenging. In particular,
burns patients will often continue to manifest features of systemic in-
ﬂammation, irrespective of the adequacy of treatment. As such, titrating
doses to achieve a desired plasma concentration, represents a pharma-
cologically robust approach, albeit is frequently unavailable, due to the
technology required. In this fashion, prior observational data has rein-
forced the utility of TDM in optimizing beta-lactam concentrations
[99]. Similar data have also been reported from a randomized clinical
trial in the critically ill [146], while limited evidence appears to support
the role of beta-lactam TDM is improving antibiotic prescribing in burns
[70]. As such, particularly if point-of-care devices can be developed,
TDM is likely to have a growing role in optimizing drug doses in burn
patients, given the grossly distorted PK that is a hallmark of this popula-
tion. Table 1 reports proposed empiric dosages and main PK/PD targets
in burns patients either with or without renal impairment.5. Conclusions
Patients suffering major burn injury represent a unique population
of critically ill patients. Local skin and tissue damage results in systemic
inﬂammation that is characterized by marked endothelial leak, ﬂuid
shifts, and cardiovascular derangement. Clinical management focuses
on local decontamination, wound care, early debridement, and intrave-
nous ﬂuid resuscitation. The patients' clinical course from this point is
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haemodynamic perturbation. Tachycardia, thermogenesis, elevated car-
diac output, increasedmajor organ blood ﬂow, hypoalbuminaemia, and
leukocytosis are all common features. Regularly these patients develop
nosocomial infection, necessitating the application of antibiotic therapy.
Importantly, achieving adequate drug exposure in this context is crucial
to successful treatment.
In this scenario, antibiotic PK is grossly distorted. The Vd, protein bind-
ing, and CL of many of these agents are signiﬁcantly different from those
observed in healthy volunteers. For hydrophilic agents (such as beta-
lactams and aminoglycosides), these changes are marked, which particu-
larly in the case of ARC, can lead to a reduction in drug exposure when
‘standard’ doses are employed. This in turn has been associatedwith infe-
rior clinical outcomes.Moreover, thismay also promote the development
of bacterial drug resistance, and in turn, therapeutic redundancy. As such,
empirical dose selection and pharmaceutical development must consider
these features, with the application of strategies that attempt to counter
the unique PK changes encountered in this setting. Use of adequate
weight-based loading doses, more frequent dosing, and continuous infu-
sions, represent pharmacologically sound approaches, which will hope-
fully counter some of this variability. Similarly, the use of TDM (where
available) is highly recommended, in order to ensure adequate drug ex-
posure, particularly where clinical feedback concerning dosing can be
problematic.
These considerations highlight the complexity in drug delivery in
major burns patients. The pathophysiological changes are extreme,
and result in profound alteration in PK parameters, speciﬁcally drug ab-
sorption, distribution, metabolism and elimination. Importantly this is
not unique to antibiotic therapy, and is highly relevant to the applica-
tion of any pharmacological agent. As such, prescribers should be
aware of these issues, and should make appropriate dose modiﬁcations
as required.
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